Leerink Partnrs Issues Negative Estimate for Sanofi Earnings

Sanofi (NASDAQ:SNY - Free Report) - Equities researchers at Leerink Partnrs cut their Q4 2024 earnings per share estimates for shares of Sanofi in a research note issued to investors on Sunday, October 27th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of $0.83 per share for the quarter, down from their previous estimate of $0.94. The consensus estimate for Sanofi's current full-year earnings is $4.25 per share. Leerink Partnrs also issued estimates for Sanofi's FY2025 earnings at $4.67 EPS.

A number of other research firms also recently weighed in on SNY. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, July 26th. Citigroup upgraded Sanofi to a "strong-buy" rating in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Monday, October 14th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $57.50.

Sanofi Stock Performance

NASDAQ SNY traded down $0.53 on Tuesday, reaching $53.83. The stock had a trading volume of 1,934,077 shares, compared to its average volume of 2,039,439. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a fifty day moving average of $56.06 and a two-hundred day moving average of $51.89. Sanofi has a 1-year low of $44.05 and a 1-year high of $58.97. The company has a market cap of $136.61 billion, a P/E ratio of 27.46, a price-to-earnings-growth ratio of 1.55 and a beta of 0.60.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $1.35. The business had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. Sanofi had a return on equity of 20.59% and a net margin of 9.96%. The firm's revenue was up 12.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.55 EPS.

Institutional Investors Weigh In On Sanofi

Large investors have recently added to or reduced their stakes in the business. Manning & Napier Advisors LLC acquired a new stake in Sanofi during the second quarter worth approximately $13,725,000. Mount Yale Investment Advisors LLC grew its stake in Sanofi by 44.3% in the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company's stock valued at $2,027,000 after acquiring an additional 12,806 shares during the period. Jennison Associates LLC grew its stake in Sanofi by 18.9% in the first quarter. Jennison Associates LLC now owns 189,622 shares of the company's stock valued at $9,216,000 after acquiring an additional 30,115 shares during the period. Sei Investments Co. grew its stake in Sanofi by 9.3% in the first quarter. Sei Investments Co. now owns 554,028 shares of the company's stock valued at $26,926,000 after acquiring an additional 47,297 shares during the period. Finally, Janney Montgomery Scott LLC grew its stake in Sanofi by 10.4% in the first quarter. Janney Montgomery Scott LLC now owns 307,627 shares of the company's stock valued at $14,951,000 after acquiring an additional 29,082 shares during the period. Institutional investors and hedge funds own 10.04% of the company's stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.